Biomaterial Database

Enhancement and suppression by actinomycin D of a Vero cell nontransmissible measles infection. 1979

S H Winston, and R Rustigian

The effect of low doses of actinomycin D on Vero cell nontransmissible measles infection produced after cocultivation with a HeLa subline with persistent defective infection by Edmonston measles virus was examined by pretreatment of Vero cells with the drug and treatment at 1, 4, and 7 days after Vero cell infection. Pretreatment enhanced focal formation of viral immunofluorescent Vero cell syncytia but did not induce synthesis of detectable amounts od cocultures suppressed syncytial formation, and treatment of 4- and 7-day-old cocultures had little, if any, effect on syncytial formation. Pretreatment also eliminated a transient resistance to homologous superinfection. A possible relation of these findings to the presence of a cell-associated viral inhibitor in the persistently infected HeLa cells is discussed.

UI	MeSH Term	Description	Entries
D008459	Measles virus	The type species of MORBILLIVIRUS and the cause of the highly infectious human disease MEASLES, which affects mostly children.	Edmonston virus
D002455	Cell Division	The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.	M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460	Cell Line	Established cell cultures that have the potential to propagate indefinitely.	Cell Lines,Line, Cell,Lines, Cell
D003609	Dactinomycin	A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006367	HeLa Cells	The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays.	Cell, HeLa,Cells, HeLa,HeLa Cell
D006389	Hemagglutinins, Viral	Specific hemagglutinin subtypes encoded by VIRUSES.	Viral Hemagglutinin,Viral Hemagglutinins,Hemagglutinin, Viral
D000998	Antiviral Agents	Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.	Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral